Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. (Q52919884)

9 May 2018

title

Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. (English)

1 reference

9 May 2018

chronic lymphocytic leukemia

1 reference

1 reference

Rosanne St Bernard

1 reference

9 May 2018

Cyrus C Hsia

series ordinal

1 reference

9 May 2018

publication date

3 September 2015

1 reference

9 May 2018

published in

Annals of Hematology

1 reference

9 May 2018

volume

1 reference

9 May 2018

issue

1 reference

9 May 2018

page(s)

2077-2079

1 reference

9 May 2018

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2487-8

Recent findings on genetics of systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2487-8

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2487-8

The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2487-8

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2487-8

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2487-8

10.1007/S00277-015-2487-8

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018